So proud of Evolution Road’s own Brian Stevens for being named to MM&M’s prestigious 40 Under 40 list. Brian is a thought-leader in driving digital innovation and is among amazing company on this list. Congrats to Brian and all the 40 Under 40 award winners!
Honored to participate with Karima Sharif from Publicis Health Media as well as Steve Silvestro and Eze Abosi from OptimizeRx on the MM&M webcast panel discussion around Life Science Digital Engagement and Non-Personal Promotion during the COVID-19 Pandemic.
So many interesting and important dynamics to discuss. Looking forward to it.
Panel is Tue May 5 at 1pm ET, register here:
I am so proud and humbled to celebrate Evolution Road’s 20th Anniversary this month. Not many small businesses make it this far, especially those that have faced 9/11, the Great Recession and now the Pandemic.
The sense of heartbreak and loss we all face today was unimaginable a few short weeks ago. Yet the strength of our global community is far stronger than this pandemic. People across the world have risen to its challenge. People in every one of our neighborhoods goes to work on the front lines of healthcare every day to stand and face this challenge and help people in desperate need. While we have a ways to go, I know we will all stand strong and stand together, and we will make it through.
I had hoped to celebrate this milestone in ER’s history with a great party, but my sense of what matters has changed. I now celebrate that my family, friends, Evolution Road colleagues and clients are still safe for the most part. I now celebrate that our empty nest at home isn’t so empty anymore and that I’ve had the amazing opportunity to spend so much quality time with my two college-aged kids (of course they may not see it the same way 😉). I celebrate when I see a friend passing by walking their dog and we get the chance to say hi and catch up. I celebrate the opportunity to get a bagel at our local bagel store (observing all appropriate social distancing protocols of course) and paying 10x for my bagel so they can give the extra $ to their employees who are struggling to make ends meet.
I now celebrate the important big things, and the important little things that are so much more important to me now than they were 6 weeks ago. Certainly not what I expected, but grateful nonetheless.
On April 30, I proudly kicked off the inaugural Digital Health for Pharma (DH4P) annual conference on behalf of Evolution Road. In the early days of digital marketing I had the pleasure of chairing the ePharma Summit which was a great way for the life science industry to come together and learn, share and connect with one another. With so many similarities between the evolution of digital marketing and the current and likely future path of digital health, we believed there was a need to create the first conference specifically focused on how life science companies can drive commercial value through digital health.
The speaker faculty was unparalleled, particularly for a first year conference. Many Pharmaceutical manufacturers attended including Pfizer, GSK, BMS, Celgene, Sanofi, Novo Nordisk, Bayer, UCB, Boehringer Ingelheim, Ferring, Lifescan, Novartis, BTG, Irwonwood, Abbvie, Roche, Adhera Therapeutics and others. We also gained diverse perspectives from healthcare provider and payer organizations such as Humana, Highmark and Jefferson Health as well as from digital health companies such as Akili, Propeller, Click Therapeutics and PackHealth.
We created the conference to support the dialogue about digital health value models for life sciences. Here is an overview of the different types of value models that we shared at DH4P:
INVEST: Equity investments in digital health companies via corporate pharma venture or innovation funds, Acquisition (i.e., Roche’s acquisition of FlatIron), Joint Venture (i.e., Sanofi + Verily forming Onduo)
INCUBATE / ACCELERATE: Internal efforts to support digital health startups (i.e., JLABS, Novartis Biome, Bayer Grants4Apps) or support of digital health companies via external organizations (i.e., Matter + Novo, J&J + Plug & Play)
COMMERCIALIZE: Typically BD&L partnerships with digital health technology organizations that leverage the life science organization’s commercialization capabilities to help bring the digital health technology to market (i.e., Novartis/Sandoz + Pear reSET-O)
COLLABORATE: Life science collaboration with digital health companies to leverage their technologies in an effort to achieve brand and customer goals (i.e., Boehringer Ingelheim + Propeller Health)
CO-DEVELOP: Jointly developing a digital health solution, utilizing an existing platform/asset from a digital health company and the R&D capabilities from a life science organization; typically includes governmental regulatory approval (i.e., Otsuka + Proteus, Pear/Thrive + Novartis in Schizophrenia)
If you would like additional perspective on these value models or Evolution Road’s point of view on driving commercial impact for pharma with digital health or digital marketing, “ask an expert” below.
Recent Comments